- Home
- NPFD vs EVMN Comparison
NPFD vs EVMN Comparison
Compare NPFD & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NPFD | EVMN |
|---|---|---|
| Founded | N/A | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 454.3M | 405.2M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | NPFD | EVMN |
|---|---|---|
| Price | $18.58 | $12.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $43.88 |
| AVG Volume (30 Days) | 66.3K | ★ 445.8K |
| Earning Date | 01-01-0001 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 85.71 |
| 52 Week Low | $17.59 | $10.47 |
| 52 Week High | $20.12 | $33.20 |
Technical Indicators
Market Signals| Indicator | NPFD | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 52.30 | 40.78 |
| Support Level | $18.51 | $12.07 |
| Resistance Level | $18.87 | $15.06 |
| Average True Range (ATR) | 0.12 | 0.70 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 48.53 | 4.36 |
Price Performance
Historical ComparisonAbout NPFD Nuveen Variable Rate Preferred & Income Fund
Nuveen Variable Rate Preferred&Income is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The fund invests a majority of its assets in variable-rate preferred securities and other variable-rate income-producing securities. The rest of its investments can be made in contingent capital securities or contingent convertible securities, convertible securities, corporate debt securities, U.S. government securities, residential and commercial mortgage-backed securities, fixed-rate preferred securities, senior loans and loan participations and assignments, sovereign debt instruments, debt securities issued by supranational agencies, and/or taxable and tax-exempt municipal bonds.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.